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using 5.0% B ⁄ b; thus, 99.2% of all staphylococcal
isolates were detected within 48 h by the PF
procedure, while only 63.3%were detected by the
FA procedure within this period. This observation
suggests that a signiﬁcant reduction in the turn-
around time is possible, and supports a decision
to take 48 h as the time limit for stopping
antibiotic treatment in the PICU population. For
staphylococci, the diagnostic yield of the PF
procedure was not improved by prolonging the
incubation period to > 72 h.
Staphylococci are currently the major causative
organisms of nosocomial sepsis in neonatal and
paediatric ICUs [14,15]. Child mortality from
central nervous system sepsis has been estimated
to be 1.3%, while c. 50% of late-onset infections
are related to the central nervous system [16,17].
The results of this study indicate that 2.5% B ⁄b
(the PF procedure) is more appropriate for use in
PICUs than the 5.0% B ⁄ b (FA) procedure, because
it results in the shortest TTD for staphylococci and
a smaller blood volume is required.
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ABSTRACT
The clinical signiﬁcance of discontinuing routine
antibiotic susceptibility testing (AST) of coagu-
lase-negative Staphylococcus (CNS) isolates from
blood cultures was investigated. Prospectively,
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AST was requested primarily for patients with
serious underlying illnesses. Antibiotic use did
not change signiﬁcantly when AST was not
performed routinely. Laboratory cost savings
were 75% if AST was not performed, but more
specimens were submitted from these patients.
Oxacillin resistance in coagulase-negative staphy-
lococci from blood cultures has remained > 70%
since implementation of this protocol, while
annual vancomycin utilisation has shown only
small, incremental increases. Therefore, it is sug-
gested that routine AST of CNS isolates from
blood culture is not essential.
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Coagulase-negative staphylococci are the leading
cause of nosocomial bloodstream infections, espe-
cially in intensive care settings [1,2], but, as part of
the normal skin ﬂora, they are also common
contaminants of blood cultures [3]. Antibiotic
susceptibility testing (AST) may be of little clinical
value, and there is no consensus regarding the
signiﬁcance of coagulase-negative Staphylococcus
(CNS) isolates obtained from blood cultures. This
report describes a pilot study inwhich routine AST
of CNS-positive blood cultures was discontinued.
Susceptibility testing was performed only upon
request. Outcome measures evaluated were: (1)
trends of empirical therapy with vancomycin; and
(2) the ﬁnancial savings to the laboratory. Vanco-
mycin usage and antibiotic resistance patterns for
coagulase-negative staphylococci were examined.
Morbidity and mortality were not measured.
All inpatients and outpatients with at least one
CNS-positive blood culture between 15 May 1999
and 14 September 1999 from the University of
Alberta Hospital or the W.W. Cross Cancer
Institute were included. For adults, a single
specimen collection comprised three blood cul-
ture vials: an aerobic and anaerobic vial from one
body site, plus a single aerobic vial from a second
site. A bacteraemic episode was deﬁned as at least
one positive vial from a single specimen collec-
tion. For paediatric patients (aged < 17 years), a
single aerobic vial was collected.
Samples were taken following cleansing of the
skin with an alcohol 70% v ⁄ v swab at the veni-
puncture site. Standard procedures were followed
for the inoculation of BACTEC blood culture vials
(Becton Dickinson Diagnostic Systems, Sparks,
MD, USA), and specimens were incubated in the
BACTEC 9240 automated system (Becton Dickin-
son Diagnostic Systems). Positive vials with an
initial Gram’s stain suggesting Staphylococcus spp.
were subcultured on blood and chocolate agar
plates. Gram’s stain, colony morphology, a posit-
ive catalase result, a negative tube coagulase result
and bacitracin resistance were used to identify
CNS. Susceptibility testing was performed with
the Vitek automated system GPS-SV cards (bio-
Me´rieux, Hazelwood, MO, USA). Oxacillin sus-
ceptibilities were determined by disk-diffusion,
using the breakpoints for coagulase-negative sta-
phylococci available at the time of the study [4].
Once the initial Gram’s stain had been examined,
the responsible clinician was informed of the
positive blood culture. There was no difference in
procedure for any patient group. In the prospect-
ive part of the study, clinicians were notiﬁed that
AST would be performed if requested.
Laboratory data were collected from computer
records. Clinical information was obtained by
chart review. Fisher’s exact test was used to
calculate two-sided p values (InStat; GraphPad
Software Inc., San Diego, CA, USA), with p < 0.05
considered to be signiﬁcant.
During phase 1 (15 May 1999–14 July 1999),
12.5% (426 ⁄ 3414) of blood cultures were positive,
compared with 14.9% (496 ⁄ 3338) during phase 2
(15 July 1999–14 September 1999). Overall, CNS
Table 1. Patient demographics and blood culture data
Characteristic Phase 1 (%) Phase 2 (%) p
Gender
Male 48 (57.8%) 55 (64.7%) 0.43
Female 35 (42.2%) 30 (35.3%)
Age
Median, years 52 49
Range 7 days–92 years 1 day–90 years
Underlying situation
Adult critical care 26 (31.3%) 27 (31.8%) 1.00
PICU ⁄NICU 10 (12.0%) 8 (9.4%) 0.63
Haemodialysis 8 (9.6%) 14 (16.5%) 0.11
Haematological ⁄ oncology 5 (6.0%) 6 (7.1%) 1.00
Blood culture collectiona
Peripheral venipuncture 47 (33.8%) 43 (26.1%) 0.17
Central site
CVC 62 (44.6%) 63 (38.2%) 0.29
Permcath 24 (17.3%) 39 (23.6%) 0.20
Broviac 6 (4.3%) 21 (12.7%) 0.014
aData for those specimens for which information was available.
PICU ⁄NICU, paediatric intensive care unit ⁄neonatal intensive care unit; CVC,
central venous catheter.
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isolates were obtained from 68.5% (632 ⁄ 922) of
positive specimens from 168 patients. Patients in
the two phases of the study were similar with
regard to age, gender and underlying conditions
(Table 1). Signiﬁcantly more blood culture
specimens were drawn from Broviac catheters in
the second group (p 0.014).
During phase 1, there were 151 CNS isolates
from 83 patients and 128 bacteraemic episodes.
Nineteen patients had two or more bacteraemic
episodes. Vitek detected 109 (72.2%) isolates that
were oxacillin-resistant; one additional oxacillin-
resistant isolate was detected by disk-diffusion.
Initially, 35 (27%) of 128 isolates were considered
to be skin contaminants; of these, 65 (50.8%) were
left untreated (Table 2).
During phase 2, 189 CNS isolates were recov-
ered from 85 patients; 28 patients had multiple
bacteraemic episodes. AST was requested and
performed for 54 isolates. Reasons included a
deteriorating clinical status, repeatedly positive
blood cultures (whether or not antibiotic therapy
had been initiated), and the presence of an
indwelling central venous catheter with associ-
ated soft tissue inﬂammation. Of these 54 isolates,
Vitek detected 40 (74.1%) that were oxacillin-
resistant; disk-diffusion detected one additional
oxacillin-resistant isolate. All isolates were sus-
ceptible to vancomycin.
Of the 148 bacteraemic episodes in the second
group, 38 (25.7%) were considered initially to be
skin contamination; however, 68 (45.9%) were not
treated with antibiotics (p 0.47). Of the remaining
80 episodes, 17 (21.3%) were treated with a
b-lactam agent; of these, ten (58.8%) were proven
subsequently to be oxacillin-resistant or were not
tested. Of the 54 susceptibility tests performed
during the prospective phase, three included spec-
imens with more than onemorphotype (three with
two types; onewith three types). These 50 episodes
represented 37 patients, 22 of whom had blood
cultures fromwhichCNS isolateswere obtained on
at least two occasions. Of the 50 patients who
yielded CNS isolates for which AST was per-
formed, 25 were treated with vancomycin, and
sevenwith a b-lactam. Seventeen patients were not
given antimicrobial agents, and one was given
clindamycin; empirical use of vancomycin did not
differ signiﬁcantly (p 0.77).Oxacillin resistancehas
remained at > 70% among tested blood culture
CNS isolates since 2000 (70.2–90.1% resistant; 96–
178 isolates tested annually). Total vancomycin
usage has increased annually since the protocol
change (from 9701 g in 1999 to 12 142 g in 2004).
Analysis of laboratory costs for labour and
materials for AST of CNS-positive blood culture
isolates indicated estimated annual savings of
> 8000 US $ (6500 Euro). Misinterpretation of
CNS-positive blood culture specimens is a major
laboratory and clinical expense. False-positive
results account for the greatest proportion of the
cost, becauseof theextra laboratoryworkandexcess
antibiotic usage, especially of vancomycin [5].
The number of bacteraemic episodes treated
with antibiotics did not differ signiﬁcantly
between the two phases. Vancomycin was the
agent used most commonly, with or without
susceptibility results, and its use did not increase
signiﬁcantly. During phase 2, AST was performed
primarily for patients with serious underlying
illnesses, and those with multiple positive speci-
mens from different sites. Although there were
signiﬁcantly more blood cultures drawn from
Broviac sites in the second group, this does not
suggest that these patients weremore ill than those
in phase 1, as the overall proportions of specimens
collected from central sites were similar.
There was a 75% decrease in laboratory AST
costs although, initially, more blood culture spec-
imens from patients with a blood CNS isolate were
sent to the laboratory, and there were more CNS-
positive cultures, which may have offset a small
portion of these savings. Clinicians may use mul-
tiple positive blood cultures as a major criterion in
theirdecision to treat apatientactively, even though
this may not be a reliable measure of true infection
or contamination [6–11]. There is no standard for
laboratory and clinical decisions regarding CNS-
positive blood cultures. Most specimens are collec-
ted from patients who are symptomatic and have
underlying risk-factors. Therefore, it may be difﬁ-
cult to distinguish true infection from skin contam-
ination on a clinical basis [8,9,12–15].
Table 2. Treatment decisions before and after discontinu-
ation of routine susceptibility testing of coagulase-negative
staphylococci isolated from blood culture a
No treatment
n (%)
VAN
n (%)
ERY ⁄CLI
n (%)
b-Lactam
n (%)
Phase 1 (n = 128)b 65 (50.8) 56 (43.8) 0 (0) 7 (5.5)
Phase 2 (n = 148)b 68 (45.9) 60 (40.5) 3 (2.0) 17 (11.5)
p value 0.57 0.77 0.50 0.22
VAN, vancomycin; ERY ⁄CLI, erythromycin and ⁄ or clindamycin.
aTreatment decision based on initial Gram’s stain of positive blood culture.
bNumber of bacteraemic episodes. Some patients had more than one CNS isolate
per episode.
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In the present study, the clinician decided
whether the CNS isolate represented a true
bacteraemic episode. This did not change treat-
ment decisions, or disrupt patient care. There was
no evidence for increased resistance trends, nor
did vancomycin utilisation increase more than
would be expected, since there were also more
patients with central venous catheters, more
foreign body-related infections, and more infec-
tions overall caused by CNS, Enterococcus spp.
and methicillin-resistant Staphylococcus aureus.
Increased vancomycin use cannot, therefore,
result solely from the absence of routine AST of
blood culture CNS isolates. Ongoing review has
validated this practice and it is now laboratory
policy. The laboratory is now also performing AST
only upon request for CNS isolates from central
venous catheters in the same patient populations.
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RESEARCH NOTE
Activity of ﬁve quinolones, three macrolides
and telithromycin against 12 Haemophilus
inﬂuenzae strains with different resistance
phenotypes
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ABSTRACT
Gemiﬂoxacin MICs for 12 Haemophilus inﬂuenzae
strains with different resistance phenotypes were
0.001–0.015 mg ⁄L. Gemiﬂoxacin was bactericidal
against all 12 strains after 24 h at 2 · MIC.
Ciproﬂoxacin, levoﬂoxacin, gatiﬂoxacin and
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